Strides Pharma names Nandini Matiyani Global Head of HR

Strides Pharma Science has appointed Nandini Matiyani as Executive Vice President and Global Head of Human Resources, strengthening the company’s leadership bench as it scales its global operations.

In a post on LinkedIn, Matiyani said she was “embarking on a new journey” with Strides and will lead the global HR function across the pharmaceutical group’s international footprint. She thanked Chairman Arun Kumar, Managing Director and Group CEO Badri Srinivasan, and the board for their confidence in her appointment.

Matiyani brings more than 20 years of experience in people strategy, cultural transformation and HR leadership across multinational and publicly listed organisations. She said her focus at Strides will be on strengthening capabilities, reinforcing culture and supporting the company’s ambition to deliver “better and fairer healthcare” through agility, innovation and meaningful people practices.

Strides, established in 1990 and headquartered in Bengaluru, operates in more than 100 countries, supplying regulated markets, donor-funded channels and its “in Africa for Africa” business. The company manufactures complex pharmaceutical products from sites in India, Italy, Kenya and the United States.

Matiyani said she looks forward to working with teams across geographies to build talent strength and organisational capacity as Strides accelerates its global agenda. Her appointment underscores the company’s focus on leadership development and culture building as it competes in highly regulated and cost-sensitive markets.

The company has not announced further organisational changes, but the expanded HR leadership role signals a sharper emphasis on people systems and capability building as Strides targets growth across key markets.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre